We are studying whether adding Atezolizumab to standard treatment helps patients with unresectable metastatic colorectal cancer live longer without disease progression. The trial also looks at the safety and quality of life for participants.
We are studying different ways to reduce rituximab doses in patients with rheumatoid arthritis. The goal is to find the best method to lower disease impact and activity.
We are studying the effects of OATD-01, an oral medication, on reducing lung inflammation in people with active pulmonary sarcoidosis. The trial will also look at safety, lung function, and quality of life.
We are studying whether a low dose of a specific medication can help prevent complications in elderly patients with blood cancers receiving stem cell transplants. This trial aims to improve recovery and overall outcomes after the transplant.
We are testing a new drug, BMS-986458, for people with relapsed or refractory non-Hodgkin lymphoma. The study aims to understand its safety and how it works alone and with other treatments.
We are studying whether immediate corticosteroid therapy combined with rituximab can help prevent worsening symptoms in patients with ocular myasthenia gravis. This trial looks at various health outcomes over two years.
We are testing a new combination of medications for patients with HER2-positive gastric or gastroesophageal cancer. The goal is to see if it helps clear cancer markers and improves survival compared to standard chemotherapy.
We are investigating whether a combination of evening melatonin and morning light therapy can help adults with idiopathic hypersomnia feel less sleepy. This study compares the treatment to a placebo to see if it makes a difference.
We are comparing a new biosimilar drug to Orencia® for patients with moderate to severe rheumatoid arthritis already taking methotrexate. The study will look at effectiveness, safety, and how the body reacts to the treatment.
We are studying a new medication, Etentamig, for adults with relapsed or refractory multiple myeloma who have already received multiple treatments. The goal is to see if it is more effective and safe compared to standard therapies.
We are studying whether colchicine and thiamine can help improve heart health in people with heart failure due to ischemic heart disease. The trial looks at their effects on serious heart-related events and hospital visits.
We are testing the investigational drug IDE196 to see if it can shrink tumors in patients with localized ocular melanoma before surgery. The study aims to evaluate its safety and effectiveness in improving treatment outcomes.
We are studying a new combination treatment for HLA-A2 negative metastatic uveal melanoma to see if it works better than current options. The trial will also evaluate the safety and quality of life for participants.
We are studying two ovarian stimulation methods to see which one improves quality of life and satisfaction for women seeking fertility preservation or genetic testing. This research aims to help tailor treatments based on individual needs.
We are evaluating the safety of a new treatment combining tiragolumab and atezolizumab for patients with certain stages of non-small cell lung cancer after surgery and chemotherapy. This study compares it to a placebo treatment to see how well it works.
We are studying whether stopping a treatment for prostate cancer after 12 months is as effective as continuing it. This may help reduce side effects and costs for patients with low-volume metastatic castration-sensitive prostate cancer.
We are studying a new treatment for patients with HER2-low breast cancer and brain metastases to see if it helps shrink tumors and improve quality of life. This trial will also look at safety and how well patients tolerate the treatment.
We are studying whether a conventional treatment approach is safer and more effective than total neoadjuvant therapy for older patients with locally advanced rectal cancer. This trial will also look at quality of life and healthcare resource use.
We are studying a new oral treatment for people with moderately to severely active Crohn's disease. The trial aims to see if it helps improve symptoms and overall health compared to a placebo.
We are studying whether golcadomide can improve outcomes for patients with aggressive large B-cell lymphoma after receiving CAR T-cell therapy. The trial will look at response rates and safety in those at high risk of relapse.